Granted Patent
B2
US 12,187,812 · App. 17/973,133 · Granted Jan 7, 2025
IBAT inhibitors for the treatment of liver diseases
Inventors:
Per-Göran Gillberg (Mölndal, SE); Hans Graffner (Helsingborg, SE); Ingemar Starke (Gothenburg, SE)
Assignee:
Albireo AB
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention regards specific IBAT inhibitors useful in the prophylaxis and/or treatment of a liver disease. It also relates to compositions comprising these IBAT inhibitors, a method for treatment of the disorders and a kit comprising the substances or the compositions.
Claims (10)
1. A method for treating a bile acid dependent disease, the method comprising orally administering to a subject in need of such treatment a therapeutically effective amount of an IBAT inhibitor, wherein the IBAT inhibitor is 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N—{(R)-α-[N—((S)-1-carboxypropyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine, or a pharmaceutically acceptable salt thereof, wherein the bile acid dependent disease comprises a defect in the intrahepatic or extrahepatic biliary tree.
2. The method of claim 1 , wherein the subject is a pediatric subject.
3. The method of claim 1 , wherein the subject has hepatic fibrosis.
4. The method of claim 1 , wherein the subject has hepatic cirrhosis.
5. The method of claim 1 , wherein the subject has portal hypertension.
6. The method of claim 1 , wherein the subject has pruritus due to jaundice.
7. The method of claim 1 , wherein the subject has pruritus as a symptom of the bile acid dependent disease.
8. The method of claim 1 , wherein the subject has pruritus as a comorbidity.
9. The method of claim 1 , wherein the concentration of liver bile acids in the subject is decreased following administration of the IBAT inhibitor.
10. The method of claim 1 , wherein the concentration of serum bile acids in the subject is decreased following administration of the IBAT inhibitor.
Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Feb 21, 2025
From: GILLBERG, PER-GÖRAN; GRAFFNER, HANS; STARKE, INGEMAR
To: ALBIREO AB
Reel/Frame 070290/0382 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Feb 21, 2025
From: GILLBERG, PER-GÖRAN; GRAFFNER, HANS; STARKE, INGEMAR
To: ALBIREO AB
Reel/Frame 070291/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 14, 2024
From: GILLBERG, PER-GÖRAN; GRAFFNER, HANS; STARKE, INGEMAR
To: ALBIREO AB
Reel/Frame 066777/0809 →
Priority Claims (1)
SE 1051165-7
· Nov 8, 2010
· national
Continuity (6)
Continuation
13881447
Provisional Application
61410957
· Nov 8, 2010
References Cited (400)
US 3539380A
· Johnson
· 1970
[cited by applicant]
US 4172120A
· Todd et al.
· 1979
[cited by applicant]
US 4507235A
· Wunsch
· 1985
[cited by applicant]
US 5049394A
· Howard et al.
· 1991
[cited by applicant]
US 5167965A
· Schulz
· 1992
[cited by applicant]
US 5294448A
· Ring
· 1994
[cited by applicant]
US 5384130A
· Kamada
· 1995
[cited by applicant]
US 5422124A
· Valducci
· 1995
[cited by applicant]
US 5578316A
· Bhardwaj et al.
· 1996
[cited by applicant]
US 5663165A
· Brieaddy
· 1997
[cited by applicant]
US 5681584A
· Savastano
· 1997
[cited by applicant]
US 5723458A
· Brieaddy et al.
· 1998
[cited by applicant]
US 5811388A
· Friend et al.
· 1998
[cited by applicant]
US 5817652A
· Brieaddy et al.
· 1998
[cited by applicant]
US 5900233A
· Day
· 1999
[cited by applicant]
US 5910494A
· Brieaddy
· 1999
[cited by applicant]
US 5976811A
· Mullner et al.
· 1999
[cited by applicant]
US 5994391A
· Lee et al.
· 1999
[cited by applicant]
US 5998400A
· Brieaddy et al.
· 1999
[cited by applicant]
US 6020330A
· Enhsen et al.
· 2000
[cited by applicant]
US 6069167A
· Sokol
· 2000
[cited by applicant]
US 6277831B1
· Frick et al.
· 2001
[cited by applicant]
US 6346527B1
· Takanaka et al.
· 2002
[cited by applicant]
US 6355672B1
· Yasuma et al.
· 2002
[cited by applicant]
US 6387924B2
· Lee et al.
· 2002
[cited by applicant]
US 6387944B1
· Frick et al.
· 2002
[cited by applicant]
US 6426340B1
· Gibson et al.
· 2002
[cited by applicant]
US 6562860B1
· Keller et al.
· 2003
[cited by applicant]
US 6592900B1
· Buhler
· 2003
[cited by applicant]
US 6635280B2
· Shell et al.
· 2003
[cited by applicant]
US 6642269B2
· Frick et al.
· 2003
[cited by applicant]
US 6676979B2
· Marlett et al.
· 2004
[cited by applicant]
US 6784201B2
· Lee et al.
· 2004
[cited by applicant]
US 6906058B2
· Starke et al.
· 2005
[cited by applicant]
US 6943189B2
· Keller et al.
· 2005
[cited by applicant]
US 7019023B2
· Frick et al.
· 2006
[cited by applicant]
US 7125864B2
· Starke et al.
· 2006
[cited by applicant]
US 7132416B2
· Starke et al.
· 2006
[cited by applicant]
US 7132557B2
· Wilkes et al.
· 2006
[cited by applicant]
US 7192945B2
· Starke et al.
· 2007
[cited by applicant]
US 7192946B2
· Starke et al.
· 2007
[cited by applicant]
US 7192947B2
· Starke et al.
· 2007
[cited by applicant]
US 7226943B2
· Starke et al.
· 2007
[cited by applicant]
US 7238684B2
· Starke et al.
· 2007
[cited by applicant]
US 7514421B2
· Abrahamsson et al.
· 2009
[cited by applicant]
US 7615536B2
· Frick et al.
· 2009
[cited by applicant]
US 7767229B1
· Milne et al.
· 2010
[cited by applicant]
US 7923468B2
· Frick et al.
· 2011
[cited by applicant]
US 7939061B2
· Prakash et al.
· 2011
[cited by applicant]
US 7956085B2
· Frick et al.
· 2011
[cited by applicant]
US 8048413B2
· Huguet
· 2011
[cited by applicant]
US 8067584B2
· Starke et al.
· 2011
[cited by applicant]
US 8101583B2
· Glombik et al.
· 2012
[cited by applicant]
US 8106023B2
· Glombik et al.
· 2012
[cited by applicant]
US 9023368B2
· Basit et al.
· 2015
[cited by applicant]
US 9295677B2
· Ling et al.
· 2016
[cited by applicant]
US 9339480B2
· Young et al.
· 2016
[cited by applicant]
US 9409875B2
· Bohlin et al.
· 2016
[cited by applicant]
US 9684018B2
· Horanzy
· 2017
[cited by applicant]
US 9688720B2
· Gillberg et al.
· 2017
[cited by applicant]
US 9694018B1
· Gillberg et al.
· 2017
[cited by applicant]
US 9701649B2
· Bohlin et al.
· 2017
[cited by applicant]
US 9745276B2
· Bohlin et al.
· 2017
[cited by applicant]
US 9872844B2
· Zernel et al.
· 2018
[cited by applicant]
US 20020054903A1
· Tyler et al.
· 2002
[cited by applicant]
US 20020142054A1
· Marlett et al.
· 2002
[cited by applicant]
US 20030124088A1
· Masuda et al.
· 2003
[cited by applicant]
US 20030125316A1
· Keller et al.
· 2003
[cited by applicant]
US 20030153541A1
· Dudley et al.
· 2003
[cited by applicant]
US 20030153607A1
· Glinecke
· 2003
[cited by applicant]
US 20030199515A1
· Mudipalli et al.
· 2003
[cited by applicant]
US 20040014806A1
· Bhat et al.
· 2004
[cited by applicant]
US 20040038862A1
· Goodwin et al.
· 2004
[cited by applicant]
US 20040062745A1
· Green et al.
· 2004
[cited by applicant]
US 20040077625A1
· Tremont et al.
· 2004
[cited by applicant]
US 20040082647A1
· Babiak et al.
· 2004
[cited by applicant]
US 20040176438A1
· Tremont et al.
· 2004
[cited by applicant]
US 20050089572A1
· Kumar
· 2005
[cited by applicant]
US 20050124557A1
· Lindqvist
· 2005
[cited by applicant]
US 20050197376A1
· Kayakiri et al.
· 2005
[cited by applicant]
US 20050215882A1
· Chenevert et al.
· 2005
[cited by applicant]
US 20050287178A1
· Steed
· 2005
[cited by applicant]
US 20060083790A1
· Anderberg et al.
· 2006
[cited by applicant]
US 20060210633A1
· Dharmadhikari
· 2006
[cited by applicant]
US 20070197522A1
· Edwards et al.
· 2007
[cited by applicant]
US 20070237818A1
· Malcom et al.
· 2007
[cited by applicant]
US 20080193543A1
· Morello
· 2008
[cited by applicant]
US 20080207592A1
· Frick et al.
· 2008
[cited by applicant]
US 20090131395A1
· Antonelli et al.
· 2009
[cited by applicant]
US 20100286122A1
· Belyk
· 2010
[cited by applicant]
US 20110152204A1
· Gedulin et al.
· 2011
[cited by applicant]
US 20110294767A1
· Gedulin et al.
· 2011
[cited by applicant]
US 20120114588A1
· Starke et al.
· 2012
[cited by applicant]
US 20120157399A1
· Young et al.
· 2012
[cited by applicant]
US 20130108573A1
· Gedulin et al.
· 2013
[cited by applicant]
US 20130109671A1
· Gedulin et al.
· 2013
[cited by applicant]
US 20130225511A1
· Gillberg et al.
· 2013
[cited by applicant]
US 20130236541A1
· Gillberg et al.
· 2013
[cited by applicant]
US 20140275090A1
· Gedulin et al.
· 2014
[cited by applicant]
US 20150031636A1
· Gillberg et al.
· 2015
[cited by applicant]
US 20150031637A1
· Gillberg et al.
· 2015
[cited by applicant]
US 20170143738A1
· Ando et al.
· 2017
[cited by applicant]
US 20170182059A1
· Gillberg et al.
· 2017
[cited by applicant]
US 20170182115A1
· Gillberg et al.
· 2017
[cited by applicant]
US 20180264031A1
· Gillberg et al.
· 2018
[cited by applicant]
US 20190046451A1
· Gillberg et al.
· 2019
[cited by applicant]
US 20190276493A1
· Bhat et al.
· 2019
[cited by applicant]
US 20200046757A1
· Gillberg et al.
· 2020
[cited by applicant]
US 20200046758A1
· Gillberg et al.
· 2020
[cited by applicant]
US 20200330545A1
· Gillberg et al.
· 2020
[cited by applicant]
US 20210171479A1
· Gillberg
· 2021
[cited by applicant]
US 20230049950A1
· Gillberg et al.
· 2023
[cited by applicant]
US 20230330176A1
· Gillberg et al.
· 2023
[cited by applicant]
US 20230338392A1
· Lindström et al.
· 2023
[cited by applicant]
US 20230398125A1
· Lindström et al.
· 2023
[cited by applicant]
US 20240067617A1
· Starke et al.
· 2024
[cited by applicant]
CA 2065151
· 1991
[cited by applicant]
DE 3930168
· 1991
[cited by applicant]
DE 19825804
· 2000
[cited by applicant]
EP 0278464
· 1988
[cited by applicant]
EP 0489423
· 1991
[cited by applicant]
EP 0372542
· 1992
[cited by applicant]
EP 0573848
· 1993
[cited by applicant]
EP 0549967
· 1993
[cited by applicant]
EP 0624593
· 1994
[cited by applicant]
EP 0624594
· 1994
[cited by applicant]
EP 0624595
· 1994
[cited by applicant]
EP 0624596
· 1994
[cited by applicant]
EP 0594570
· 1995
[cited by applicant]
EP 0864582
· 1998
[cited by applicant]
EP 1173205
· 2000
[cited by applicant]
EP 1045840
· 2000
[cited by applicant]
EP 1273307
· 2003
[cited by applicant]
EP 1535913
· 2005
[cited by applicant]
EP 1719768
· 2006
[cited by applicant]
EP 2144599
· 2010
[cited by applicant]
EP 3210977
· 2017
[cited by applicant]
GB 2262888
· 1996
[cited by applicant]
GE 1573487
· 1980
[cited by applicant]
JP 2000513028
· 2000
[cited by applicant]
JP 2004516285
· 2004
[cited by applicant]
JP B3665055
· 2005
[cited by applicant]
JP 2006124695
· 2006
[cited by applicant]
JP B4870552
· 2012
[cited by applicant]
JP 2013541584
· 2013
[cited by applicant]
JP 2013542953
· 2013
[cited by applicant]
JP B5421326
· 2014
[cited by applicant]
JP H02258719
· 2019
[cited by applicant]
RU 2314104
· 2008
[cited by applicant]
WO WO199103249
· 1991
[cited by applicant]
WO WO199316055
· 1993
[cited by applicant]
WO WO199400111
· 1994
[cited by applicant]
WO WO199418183
· 1994
[cited by applicant]
WO WO199418184
· 1994
[cited by applicant]
WO WO199605188
· 1996
[cited by applicant]
WO WO199608484
· 1996
[cited by applicant]
WO WO199616051
· 1996
[cited by applicant]
WO WO199733882
· 1997
[cited by applicant]
WO WO199803818
· 1998
[cited by applicant]
WO WO199807449
· 1998
[cited by applicant]
WO WO199838182
· 1998
[cited by applicant]
WO WO199840375
· 1998
[cited by applicant]
WO WO199856757
· 1998
[cited by applicant]
WO WO199901149
· 1999
[cited by applicant]
WO WO199932478
· 1999
[cited by applicant]
WO WO199935135
· 1999
[cited by applicant]
WO WO199964409
· 1999
[cited by applicant]
WO WO199964410
· 1999
[cited by applicant]
WO WO200001687
· 2000
[cited by applicant]
WO WO200038725
· 2000
[cited by applicant]
WO WO200038726
· 2000
[cited by applicant]
WO WO200038727
· 2000
[cited by applicant]
WO WO200038728
· 2000
[cited by applicant]
WO WO200038729
· 2000
[cited by applicant]
WO WO200047568
· 2000
[cited by applicant]
WO WO200061568
· 2000
[cited by applicant]
WO WO200062810
· 2000
[cited by applicant]
WO WO200134570
· 2001
[cited by applicant]
WO WO200160807
· 2001
[cited by applicant]
WO WO200166533
· 2001
[cited by applicant]
WO WO200168096
· 2001
[cited by applicant]
WO WO200168637
· 2001
[cited by applicant]
WO WO200208211
· 2002
[cited by applicant]
WO WO200209815
· 2002
[cited by applicant]
WO WO200232428
· 2002
[cited by applicant]
WO WO200250051
· 2002
[cited by applicant]
WO WO200253548
· 2002
[cited by applicant]
WO WO2003020710
· 2003
[cited by applicant]
WO WO2003022286
· 2003
[cited by applicant]
WO WO2003022804
· 2003
[cited by applicant]
WO WO2003022825
· 2003
[cited by applicant]
WO WO2003022830
· 2003
[cited by applicant]
WO WO2003043992
· 2003
[cited by applicant]
WO WO2003051821
· 2003
[cited by applicant]
WO WO2003051822
· 2003
[cited by applicant]
WO WO2003061663
· 2003
[cited by applicant]
WO WO2003091232
· 2003
[cited by applicant]
WO WO2003106482
· 2003
[cited by applicant]
WO WO2004006899
· 2004
[cited by applicant]
WO WO2004020421
· 2004
[cited by applicant]
WO WO2004056748
· 2004
[cited by applicant]
WO WO2004076430
· 2004
[cited by applicant]
WO WO2004089350
· 2004
[cited by applicant]
WO WO2005082874
· 2005
[cited by applicant]
WO WO2007009655
· 2007
[cited by applicant]
WO WO2007009656
· 2007
[cited by applicant]
WO WO2008058628
· 2008
[cited by applicant]
WO WO2008058630
· 2008
[cited by applicant]
WO WO2008058631
· 2008
[cited by applicant]
WO WO2010062861
· 2010
[cited by applicant]
WO WO2010041268
· 2010
[cited by applicant]
WO WO2010106249
· 2010
[cited by applicant]
WO WO2011137135
· 2011
[cited by applicant]
WO WO2011150286
· 2011
[cited by applicant]
WO WO2012064266
· 2012
[cited by applicant]
WO WO2012064267
· 2012
[cited by applicant]
WO WO2012064268
· 2012
[cited by applicant]
WO WO2013063512
· 2013
[cited by applicant]
WO WO2013063526
· 2013
[cited by applicant]
WO WO2013168671
· 2013
[cited by applicant]
WO WO2014174066
· 2014
[cited by applicant]
WO WO2014179453
· 2014
[cited by applicant]
WO WO2015193788
· 2015
[cited by applicant]
WO WO2016062848
· 2016
[cited by applicant]
WO WO2017138876
· 2017
[cited by applicant]
WO WO2017138877
· 2017
[cited by applicant]
WO WO2017138878
· 2017
[cited by applicant]
WO WO2019017724
· 2019
[cited by applicant]
WO WO2019032026
· 2019
[cited by applicant]
WO WO2019032027
· 2019
[cited by applicant]
WO WO2019172834
· 2019
[cited by applicant]
WO WO2019234077
· 2019
[cited by applicant]
WO WO2019245448
· 2019
[cited by applicant]
WO WO2019245449
· 2019
[cited by applicant]
WO WO2020194531
· 2020
[cited by applicant]
WO WO2020161216
· 2020
[cited by applicant]
WO WO2020161217
· 2020
[cited by applicant]
WO WO2020167958
· 2020
[cited by applicant]
WO WO2020167964
· 2020
[cited by applicant]
WO WO2020167981
· 2020
[cited by applicant]
WO WO2020167985
· 2020
[cited by applicant]
WO WO2021110883
· 2021
[cited by applicant]
WO WO2021110884
· 2021
[cited by applicant]
WO WO2021110885
· 2021
[cited by applicant]
WO WO2021110886
· 2021
[cited by applicant]
WO WO2021110887
· 2021
[cited by applicant]
WO WO2022029101
· 2022
[cited by applicant]
WO WO2022101379
· 2022
[cited by applicant]
WO WO2022117778
· 2022
[cited by applicant]
WO WO2022253997
· 2022
[cited by applicant]
WO WO2023203248
· 2023
[cited by applicant]
WO WO2024008766
· 2024
[cited by applicant]
[No Author Listed], “Practical Pharmaceutical Preparation Technology”, People's Medical Publishing House, Jan. 1999, 286-287 (Machine Translation).
[cited by applicant]
A Long-Term, Open-Label Study of LUM001 With a Double-Blind, Placebo Controlled, Randomized Drug Withdrawal Period to Evaluate Safety and Efficacy in Children With Alagille Syndrome (Iconic), Clinical Trials.gov, Jun. 9…
[cited by applicant]
AASLD: 2017 68th Annual Meeting of the American Association for the Study of Liver Diseases, Washington, DC, Oct. 20-24, 2017, (Abstract only).
[cited by applicant]
Adams et al., “Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection,” Clin. Chem. 2005, vol. 51(10), p. 1867-1873.
[cited by applicant]
Alagile Syndrome, Wikipedia, the free encyclopedia, posted on or about Feb. 11, 2005, retrieved Feb. 12, 2014, http://en.wikipedia.org/wiki/Alagille_syndrome, 3 pages.
[cited by applicant]
Alashkar et al., “Meeting Info.: 57th Annual Meeting of the American Society-of-Hematology,” Orlando, FL, USA. Dec. 5-8, 2015, Amer Soc Hematol, Blood, 2015, 126(23).
[cited by applicant]
Albireo's Lead Compound in Cholestatic Liver Diseases, A4250, Projects Against Bile Acid-Mediated Cholestatic Liver Injury in Mice, Albireo Press Release, Apr. 11, 2014, 2 pages.
[cited by applicant]
Al-Dury, “Ileal Bile Acid Transporter Inhibition for the Treatment of Chronic Constipation, Cholestatic Pruritus, and NASH,” Frontiers in Pharmacology, 2018, 9:931.
[cited by applicant]
Alissa et al., “Invited Review: Update on Progressive Familial Intrahepatic Cholestasis,” Journal of Pediatric Gastroenterology and Nutrition, 2008, 46:241-252.
[cited by applicant]
Almasio et al., “Role of S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis,” Drugs, 1990, 40 Suppl (3):111-123.
[cited by applicant]
Alonso et al., “Histologic pathology of the liver in progressive familial intrahepatic cholestasis,” Journal of Pediatric Gastroenterology and Nutrition, 14: 128-133, 1994.
[cited by applicant]
Boncristani et al., Respiratory Viruses, Encyclopedia of Microbiology, 2009, 19 pages.
[cited by applicant]
Bonge et al., “Cytostar-T Scintillating Microplate Assay for Measurement of Sodium-Dependent Bile Acid Uptake in Transfected HEK-293 Cells,” Analytical Biochemistry, 2000, 282:94-101.
[cited by applicant]
Allison et al., “Studies on mixed populations of human intestinal bacteria grown in single-stage and multistage continuous culture systems,” Appl. Environ. Microbial. 1989, 55(3):672-678.
[cited by applicant]
Alvarez et al., “Reduced hepatic expression of farnesoid X receptor in hereditary cholestasis associated to mutation in ATP8B1,” Hum Mol Genet, 2004, 13(20):2451-2460.
[cited by applicant]
Alnouti, “Bile acid sulfation: a pathway of bile acid elimination and detoxification,” Toxicological Sciences, 2009, 108(2):225-246.
[cited by applicant]
Alvarez, “Development of crystallization processes for pharmaceutical applications,” Laccei, 2007, 2E.3-1-2E.3-9.
[cited by applicant]
Alvarez, Fernando; “Treatments in chronic cholestasis in children.” Ann. Nestlé (2008) 66 p. 127-135.
[cited by applicant]
American Diabetes Association, “Management of Dyslipidemia in Adults with Diabetes,” Diabetes Care, Jan. 2003, 26(1).
[cited by applicant]
An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Subjects With Alagille Syndrome (Imagine), Clinical Trials.gov, Jan. 23, 2014, retr…
[cited by applicant]
An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Subjects With Alagille Syndrome (Imagine-II), Clincal Trials.gov, Apr. 16, 2014, re…
[cited by applicant]
Anakk et al., “Bile acids activate YAP to promote liver carcinogenesis,” Cell Rep., Nov. 27, 2013, 5(4):1060-1069.
[cited by applicant]
Angulo et al., “Independent Predictors of Liver Fibrosis in Patients With Nonalcoholic Steatohepatitis,” Hepatology, Dec. 1999, 30(6): 1356-1362.
[cited by applicant]
Angulo et al., “The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD,” Hepatology, 2007, vol. 45(4), p. 846-54.
[cited by applicant]
Angulo, “Use of ursodeoxycholic acid in patients with liver disease,” Current Gastroenterology Reports, Feb. 1, 2002, 4(1):37-44.
[cited by applicant]
Anzivino et al., “ABCB4 and ABCB11 mutations in intrahepatic cholestasis of pregnancy in an Italian population,” Dig Liver Dis., 2013, 45(3):226-232.
[cited by applicant]
Appleby et al., “Effects of conventional and a novel colonic-release bile acid sequestrant, A3384, on fibroblast growth factor 19 and bile acid metabolism in healthy volunteers and patients with bile acid diarrhoea”, Un…
[cited by applicant]
Arnell et al., “Follow-up in children with progressive familial intrahepatic cholestasis after partial external biliary diversion,” J Pediatr Gastroenterol Nutr., 2010, 51(4):494-499.
[cited by applicant]
Artursson et al., “Correlation Between Oral Drug Absorption in Humans and Apparent Drug Permeability Coefficients in Human Intestinal Epithelial (Caco-2) Cells,” Biochemical and Biophysical Research Communications, Mar.…
[cited by applicant]
Asami et al., “Treatment of children with familial hypercholesterolemia with colestilan, a newly developed bile acid-binding resin,” Atherosclerosis, 2002, 164:381-2.
[cited by applicant]
Attili et al., “Bile Acid-induced Liver Toxicity: Relation to the Hydrophobic-Hydrophilic Balance of Bile Acids,” Medical Hypotheses, 1986, 19:57-69.
[cited by applicant]
Baghdasaryan et al., “Inhibition of intestinal bile acid absorption by ASBT inhibiton A4250 protects against bile acid-mediated cholestatic liver injury in mice,” J. Hepatology, 2014, 60:S57.
[cited by applicant]
Baghdasaryan et al., “Inhibition of intestinal bile acid absorption by ASBT inhibitor A4250 protects against bile acid-mediated cholestatic liver injury in mice,” Presented at the EASL Conference, London, UK, Apr. 12, 2…
[cited by applicant]
Bajor et al., “Bile acids: short and long term effects in the intestine,” Scandanavian J. Gastro., 2010, 45:645-664.
[cited by applicant]
Balbach et al., “Pharmaceutical evaluation of early development candidates “the 100 mg-approach”,” Int J Pharm, May 4, 2004, 275(1):1-12.
[cited by applicant]
Banker et al., “Modern Pharmaceutics, 3ed”, Marcel Dekker, New York, 1996, pp. 451 and 596.
[cited by applicant]
Baker et al. “Systematic review of progressive familial intrahepatic cholestasis,” Clin Res Hepatol Gastroenterol., 2019;43:20-36.
[cited by applicant]
Cited By (3)